Elscint starts feeling health-care heat
Israeli medical imagingvendor Elscint began to feel the imaging market downturn thisyear. The vendor had unusually strong results, relative to a depressedindustry, in 1993. But revenues declined 4% in the first quarterof 1994 (end-March), to $54.2
Israeli medical imagingvendor Elscint began to feel the imaging market downturn thisyear. The vendor had unusually strong results, relative to a depressedindustry, in 1993. But revenues declined 4% in the first quarterof 1994 (end-March), to $54.2 million from $56.9 million in thesame period last year. Quarterly net income dropped from $4.5million in 1993 to $3.1 million.
Elscint cited increasing worldwide cost-containment pressuresfor medical services as well as U.S. health-care reform uncertaintyas reasons for the performance decline. Bookings for the quarterwere less than expected, resulting in a 9% decrease in Elscint'sorder backlog, the company said.
Elscint may also have been affected by an apparent downturnthis year in the nuclear medicine camera business, which had beenrelatively healthy last year (SCAN 4/6/94). The vendor is initiatingcost-cutting measures in response to the slowing business, accordingto president and CEO Shmuel Parag.
FDA Clears Virtually Helium-Free 1.5T MRI System from Siemens Healthineers
June 26th 2025Offering a cost- and resource-saving DryCool magnet technology, the Magnetom Flow.Ace MRI system reportedly requires 0.7 liters of liquid helium for cooling over the lifetime of the device in contrast to over 1,000 liters commonly utilized with conventional MRI platforms.
SNMMI: Botox May Facilitate Relief from Dry Mouth Side Effect of PSMA-Targeted Radiopharmaceuticals
June 25th 2025For patients being treated with radiopharmaceutical agents for metastatic prostate cancer, the combination of botulinum toxin and an anti-nausea patch led to a 30 percent reduction in PSMA uptake in the salivary glands, according to preliminary research findings presented at the SNMMI conference.
